A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride?

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00690950

Enrollment

Registered

2008-06-05

Start date

2008-05-31

Completion date

Unknown

Last updated

2008-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Keywords

BPH

Brief summary

Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on International Prostate Symptom score,and lower pvr based on the scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs. finasteride which only inhibits the Type II enzyme

Interventions

DRUGDutasteride

0.5mg capsule, taken once daily for 12 months

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Male * Age 50-80 * On finasteride for no less than 12 months * Willing to undergo all necessary test in the 12 month evaluation

Exclusion criteria

* History of medication non-compliance * Unwillingness to undergo/tolerate 2 blood draws * Unwillingness to tolerate/undergo 2 TRUSP

Design outcomes

Primary

Measure	Time frame
Laboratory parameters: including serum testosterone, DHT level and PSA	12 months

Secondary

Measure	Time frame
volume measurements of TRUSP and PVR	12 months
A decrease in the AUASI	12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026